Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 bimekizumab trial in moderate to severe hidradenitis suppurativa
NL-OMON52878Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bimekizumab in hidradenitis suppurativa (HS) (4 arms), sponsored by UCB. Primary endpoint: HiSCR50 at Week 16. Started Mar 2021; status: active, not recruiting.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON52878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52878.